Your browser doesn't support javascript.
loading
Botulinum-toxin-A injection following conservative management in patients with dyssynergic defaecation only improves symptoms in the short term: a retrospective study
Ganko, Annabelle G; Warwick, Andrea M; Gillespie, Christopher.
  • Ganko, Annabelle G; Queen Elizabeth II Jubilee Hospital. Functional Colorectal Unit. Coopers Plains. AU
  • Warwick, Andrea M; Queen Elizabeth II Jubilee Hospital. Functional Colorectal Unit. Coopers Plains. AU
  • Gillespie, Christopher; Queen Elizabeth II Jubilee Hospital. Functional Colorectal Unit. Coopers Plains. AU
J. coloproctol. (Rio J., Impr.) ; 44(1): 33-40, 2024. tab, ilus
Article Dans Anglais | LILACS | ID: biblio-1558288
ABSTRACT

Objective:

Dyssynergic defaecation (DD) is an important cause of chronic constipation. In patients where conservative treatments fail, injections of botulinum toxin A (BTX-A) into the puborectalis and anal sphincter muscles can be effective. Complications of this procedure are reported to be rare and generally mild. This study aimed to identify the complication rates and short- to medium-term success rates of BTX-A injections as a treatment for DD.

Methods:

A retrospective review was conducted on patients diagnosed with DD who had undergone BTX-A injections at a functional colorectal unit. Patient demographics, manometric assessment, conservative management, and injection technique were collected through a chart review. Subjective patient reports and comparison of pre- and postprocedure symptom scores were used to determine efficacy.

Results:

The 21 patients included (24 procedures, with 3 patients receiving BTX-A on two separate occasions) all received stool modification and dietary advice, and 20 patients underwent pelvic floor physiotherapy, averaging 8 sessions. The injections were universally applied under general anesthetic, primarily targeting the anal sphincter and/or puborectalis muscles. There were 6 reports of faecal urge/incontinence, with all but one being resolved within weeks. The BTX-A injection was subjectively reported as beneficial in 19 cases, averaging 4.7 months (range 1-32) of improvement. Only 2 were sustained beyond 12 months. Despite overall improvements in symptom scores from pre- to postprocedure, none were statistically significant.

Conclusion:

Following a course of conservative management, the BTX-A injection appears to be a safe treatment for DD, but only has short term efficacy. (AU)
Sujets)


Texte intégral: Disponible Indice: LILAS (Amériques) Sujet Principal: Toxines botuliniques de type A / Troubles du plancher pelvien Limites du sujet: Adulte / Adulte très âgé / Femelle / Humains / Mâle langue: Anglais Texte intégral: J. coloproctol. (Rio J., Impr.) Thème du journal: Cirurgia / Doen‡as Retais / Doen‡as do Colo / Gastroentérologie / Cirurgia Année: 2024 Type: Article Pays d'affiliation: Australie Institution/Pays d'affiliation: Queen Elizabeth II Jubilee Hospital/AU

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS


Texte intégral: Disponible Indice: LILAS (Amériques) Sujet Principal: Toxines botuliniques de type A / Troubles du plancher pelvien Limites du sujet: Adulte / Adulte très âgé / Femelle / Humains / Mâle langue: Anglais Texte intégral: J. coloproctol. (Rio J., Impr.) Thème du journal: Cirurgia / Doen‡as Retais / Doen‡as do Colo / Gastroentérologie / Cirurgia Année: 2024 Type: Article Pays d'affiliation: Australie Institution/Pays d'affiliation: Queen Elizabeth II Jubilee Hospital/AU